Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.
As the U.S. stock market navigates a mixed landscape of earnings reports and inflation data, major indexes like the S&P 500 and Nasdaq Composite are on track for gains, reflecting investor optimism ...
Four labourers were killed and 15 others injured on Thursday morning in a slab collapse at a JK Cement factory in Madhya Pradesh’s Panna district, police said. The incident took place at an ...
Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. Analyst Price Forecast Suggests 87.91% Upside As of ...